Top
Summary
All studies
Mortality
Serious outcomes
Recovery
RCTs
RCT mortality
Peer-reviewed
All outcomes

Feedback
 
Analgesics⏵
Antiandrogens⏵
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle⏵
Melatonin
Metformin
Minerals⏵
Molnupiravir
Monoclonals⏵
Naso/orophar..⏵
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins⏵
More⏵

Other
Feedback
Home
 
Top
..
All crizanlizumab studies
..
Feedback
Home
c19early.org COVID-19 treatment researchCrizanlizumabCrizanlizumab (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta
Home Adoption Other Treatments
@CovidAnalysis

Outcomes in COVID-19 crizanlizumab studies

Home
Post
Share
@CovidAnalysis
StudiesStudies
FeedbackFeedback
All studies   Mortality   Serious outcomes   Recovery   RCTs   RCT mortality   Peer-reviewed   All outcomes  
0 0.5 1 1.5+ All studies -29% 2 463 Improvement, Studies, Patients Relative Risk Mortality -33% 1 421 RCTs -29% 2 463 Late -29% 2 463 Crizanlizumab for COVID-19 c19early.org December 2024 Favorscrizanlizumab Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Leucker (DB RCT) 68% 0.32 [0.01-7.49] progression 0/22 1/20 Improvement, RR [CI] Treatment Control ACTIV-4a Solomon (RCT) -33% 1.33 [0.85-2.21] death 37/211 27/210 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.27 Late treatment -29% 1.29 [0.82-2.03] 37/233 28/230 29% higher risk All studies -29% 1.29 [0.82-2.03] 37/233 28/230 29% higher risk 2 crizanlizumab COVID-19 studies c19early.org December 2024 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.27 Effect extraction pre-specified(most serious outcome) Favors crizanlizumab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ ACTIV-4a Solomon (RCT) -33% 1.33 [0.85-2.21] 37/211 27/210 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.22 Late treatment -33% 1.33 [0.85-2.21] 37/211 27/210 33% higher risk All studies -33% 1.33 [0.85-2.21] 37/211 27/210 33% higher risk 1 crizanlizumab COVID-19 mortality result c19early.org December 2024 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.22 Favors crizanlizumab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Leucker (DB RCT) 68% 0.32 [0.01-7.49] progression 0/22 1/20 Improvement, RR [CI] Treatment Control ACTIV-4a Solomon (RCT) -33% 1.33 [0.85-2.21] death 37/211 27/210 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.27 Late treatment -29% 1.29 [0.82-2.03] 37/233 28/230 29% higher risk All studies -29% 1.29 [0.82-2.03] 37/233 28/230 29% higher risk 2 crizanlizumab COVID-19 serious outcomes c19early.org December 2024 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.27 Effect extraction pre-specified(most serious outcome) Favors crizanlizumab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Leucker (DB RCT) -35% 1.35 [0.89-2.06] no disch. 22 (n) 20 (n) Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.16 Late treatment -35% 1.35 [0.89-2.06] 22 (n) 20 (n) 35% higher risk All studies -35% 1.35 [0.89-2.06] 22 (n) 20 (n) 35% higher risk 1 crizanlizumab COVID-19 recovery result c19early.org December 2024 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.16 Favors crizanlizumab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Leucker (DB RCT) 68% 0.32 [0.01-7.49] progression 0/22 1/20 Improvement, RR [CI] Treatment Control ACTIV-4a Solomon (RCT) -33% 1.33 [0.85-2.21] death 37/211 27/210 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.27 Late treatment -29% 1.29 [0.82-2.03] 37/233 28/230 29% higher risk All studies -29% 1.29 [0.82-2.03] 37/233 28/230 29% higher risk 2 crizanlizumab COVID-19 Randomized Controlled Trials c19early.org December 2024 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.27 Effect extraction pre-specified(most serious outcome) Favors crizanlizumab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ ACTIV-4a Solomon (RCT) -33% 1.33 [0.85-2.21] 37/211 27/210 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.22 Late treatment -33% 1.33 [0.85-2.21] 37/211 27/210 33% higher risk All studies -33% 1.33 [0.85-2.21] 37/211 27/210 33% higher risk 1 crizanlizumab COVID-19 RCT mortality result c19early.org December 2024 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.22 Favors crizanlizumab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Leucker (DB RCT) 68% 0.32 [0.01-7.49] progression 0/22 1/20 Improvement, RR [CI] Treatment Control ACTIV-4a Solomon (RCT) -33% 1.33 [0.85-2.21] death 37/211 27/210 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.27 Late treatment -29% 1.29 [0.82-2.03] 37/233 28/230 29% higher risk All studies -29% 1.29 [0.82-2.03] 37/233 28/230 29% higher risk 2 crizanlizumab COVID-19 peer reviewed studies c19early.org December 2024 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.27 Effect extraction pre-specified(most serious outcome) Favors crizanlizumab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Leucker (DB RCT) 68% 0.32 [0.01-7.49] progression 0/22 1/20 Improvement, RR [CI] Treatment Control Leucker (DB RCT) 9% 0.91 [0.06-13.6] progression 1/22 1/20 Leucker (DB RCT) -35% 1.35 [0.89-2.06] no disch. 22 (n) 20 (n) ACTIV-4a Solomon (RCT) -33% 1.33 [0.85-2.21] death 37/211 27/210 ACTIV-4a Solomon (RCT) -78% 1.78 [0.93-3.24] death 25/211 14/210 ACTIV-4a Solomon (RCT) -43% 1.43 [0.86-2.33] misc. 211 (n) 210 (n) Crizanlizumab COVID-19 outcomes c19early.org December 2024 Favors crizanlizumab Favors control
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit    
Post
Share
@CovidAnalysis
FAQ
Public domain CC0 1.0